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ABSTRACT 
JENNIFER C. JARRELL 
Human Papillomavirus Vaccine Policy in the United States 
(Under the direction of RUSS TOAL, FACULTY MEMBER) 
 
HPV vaccine school entry mandates and vaccine funding by state was examined using 
the Diffusion of Innovations (DOI) theory.  The DOI was applied to HPV immunization 
policy to evaluate the rate of vaccine adoption and to determine whether associations 
existed between an empirical need for vaccine adoption and action by the states. State-
level data on political characteristics, health and policy were collected from several 
secondary sources. Data analyses were performed utilizing SPSS logistic regression 
models. Odds rations were used to evaluate the associations between the independent and 
dependent variables to determine whether there was a statistical significance level of .05. 
Cervical Cancer incidence in a state was significantly associated with HPV school entry 
mandates (proposed or enacted), but it did not show a significant association with HPV 
vaccine funding. Diffusion of vaccine innovation is slow, which may offer additional 
opportunities to evaluate effective policy strategies for coverage and use of the HPV 
vaccine.  
 
 
Index words: human papillomavirus, vaccine, immunization policy, diffusion of 
innovations 
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GLOSSARY OF TERMS 
Adenocarinoma in situ - a type of cervical cancer 
Adverse health outcomes - harmful illness, injury, or disease 
Booster - additional vaccine, which serves to lengthen the efficacy of a previous vaccine 
Cervical intraepithelial neoplasia - abnormal, precancerous cells on the cervix  
Efficacy - the ability to produce a desired effect 
Erythema - abnormal reddening of the skin 
Herd Immunity - high numbers of vaccinated people provide protection from a disease  
      to unvaccinated individuals 
 
Incidence - number of new cases of a disease within a specified time, usually a year 
Local reactions - injection site irritations such as erythema, itching, swelling 
Medical intervention - healthcare treatment 
Persistent infection - infection that the body does not clear 
Precursor lesions - precancerous lesions that left untreated can become cancerous 
Prevalence - total number of a disease cases in a population at a specified time 
Prophylaxis - preventive treatment  
Quadrivalent HPV vaccine - vaccine that covers four different human papillomavirus  
types 
 
Self-clear - the body successfully “clears” the virus without medical treatment 
Sexual debut - time when a person first becomes sexually active 
Study endpoints - primary goals of the clinical study 
Underinsured - people who have inadequate insurance coverage 
Uninsured - people who do not have health insurance coverage 
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CHAPTER I 
INTRODUCTION 
 
Since 2004, several studies have found that the Human Papillomavirus (HPV) is 
the most common sexually transmitted infection in the U.S., with an estimated 6.2 
million newly infected people annually (Centers for Disease Control and Prevention, 
2007a; Weinstock, Berman, & Cates, 2004).  In response, Merck and Company, a 
multinational pharmaceutical company, developed the first HPV vaccine, Gardasil®.  
Gardasil®, as a medical innovation, addressed the growing prevalence of HPV types 6, 
11, 16, and 18 associated cervical cancer and genital warts.  Following the completion of 
Gardasil® clinical trials, the U. S. Food and Drug Administration (FDA) evaluated the 
safety and efficacy of vaccine.  In June 2006, the FDA concluded the evaluation of 
Gardasil® and licensed the vaccine for use in the U.S. for females ages 9 to 26 years 
(Food and Drug Administration, 2006).  Within the same month, the Advisory 
Committee on Immunization Practices (ACIP), the committee charged by Secretary of 
the U. S. Department of Health and Human Services with establishing national 
immunization schedules and outlining vaccine usage, voted to add the vaccine to the 
national adolescent immunization schedule.  The ACIP recommendation for the standard 
use for the HPV vaccine is 11 and 12 year old girls, with catch-up vaccine for females 13 
to 26 (Centers for Disease Control and Prevention, 2007a).   
Since June 2006, states have been considering whether the HPV vaccine 
recommendation warrants state policy changes.  Some states are deliberating policies that 
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mandate the HPV vaccine for school entry among sixth grade girls.  Additionally, some 
states are assessing funding options to address the associated costs of mandating an 
additional vaccine.  Requiring the HPV vaccine for school entry among school-aged 
females would require additional resources, as the demand for the new vaccine would 
increase rapidly.  As noted in Chapter II, these states are evaluating whether the HPV 
vaccine creates a need for additional funds to cover the cost Gardasil® imposes on their 
vaccine programs. 
State immunization programs are experiencing an increase in the number of new, 
expensive vaccines (Institute of Medicine, 2003).  The total cost to fully vaccinate a child 
has risen from $155 in 1995 to $1,170 in 2007 (Centers for Disease Control and 
Prevention, 2007c, 2007d; Davis, Zimmerman, Wheeler, & Freed, 2002; Lee, Santoli, 
Hannan, Messonnier, et al., 2007).  Moreover, the HPV vaccine is the most expensive 
vaccine on the market to date (Centers for Disease Control and Prevention, 2007d).  
According to the 2005 childhood/adolescent immunization schedule, the HPV vaccine 
costs one-third the total amount to fully immunize a child (American Academy of 
Pediatrics, 2005).   
 
Theoretical Framework and Hypothesis 
Since Gardasil® is a medical innovation, the Diffusion of Innovation Theory can 
demonstrate the adoption of innovation policy across state populations (Cain & Mittman, 
2002; Rogers, 2003).  The scope of this research will explore factors associated with the 
innovation policy has reached a point of majority adoption.  For the purposes of this 
paper, the following concepts are presented: 
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• Majority adoption will be measured by proposed or enacted policy that would 
mandate the HPV vaccine for school entry or provide funding for the HPV 
vaccine. 
• The empirical need for vaccine adoption will be represented by a number of state 
health characteristics: cervical cancer incidence, Pap screening percentage, 
percentage of uninsured women, and the state’s United Health Foundation score. 
• Political characteristics will represent the social climate of a state.  These are 
measured by which political party controls the state’s legislature and 
gubernatorial seat.  These characteristics also serve to establish general division of 
the state’s population into groups. 
The research will evaluate: 
• Whether the empirical need for vaccine adoption is associated with policy 
adoption, and 
• Whether state political characteristics are associated with majority policy 
adoption.   
The Diffusion of Innovation theory can be used to assess whether a majority 
acceptance of this innovation is likely to exist at a particular point in time.  The 
hypothesis of this study (H1) is that there is an association between mandating use of or 
funding for the HPV vaccine and such variables as state health and political 
characteristics (for the time period studied).  The null hypothesis (Ho) is that there is no 
significant association with HPV vaccine mandating or funding policy and state 
characteristics.  
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The following Chapter II discusses HPV and the HPV vaccine, school entry vaccine 
mandates, vaccine programs and funding, and the Diffusion of Innovation theory.  
Chapter III contains the methodology and variables used in the study.  Chapter IV 
describes the descriptive and logistic regression analysis results, and the final Chapter V 
discusses the study implications, limitations and recommendations.  
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CHAPTER II 
 LITERATURE REVIEW 
 
Human Papillomavirus Background 
HPV is the most common sexually transmitted infection in the U.S.  An estimated 
6.2 million people are infected with HPV annually (Weinstock et al., 2004).  The HPV 
prevalence estimates among U.S. women ranges between 16% and 28% of the sampled 
population (Centers for Disease Control and Prevention, 2005; Dunne et al., 2007).  
Incidence, the number of new infections annually, and prevalence of HPV is most 
common among those 14 to 24 years of age (Dunne et al., 2007; Weinstock et al., 2004).  
Mathematical modeling estimates 80% of sexually active females in the U.S. contract an 
HPV infection by age 50 (Centers for Disease Control and Prevention, 2007a; Centers for 
Disease Control and Prevention, 2005; Myers, McCrory, Nanda, Bastian, & Matchar, 
2000).   
HPV infected individuals transmit the virus through genital-genital contact, most 
frequently through sexual intercourse.  Risk factors for HPV include sexual debut at a 
young age, increased number of sexual partners, sexual relations with partners that have 
had an increased number of sexual partners, and other high-risk sexual behaviors 
(Centers for Disease Control and Prevention, 2007a; Dunne et al., 2007; Winer, Lee, 
Hughes, Adam, & Kiviat, 2003).  Early age at sexual debut increases the risk of 
contracting STIs due to the increase in lifetime cumulative risk from three or more sexual 
 6 
 
partners (Dunne et al., 2007).  Having three or more lifetime sexual partners puts an 
individual at increased risk for contracting HPV (Centers for Disease Control and 
Prevention, 2007a; Dunne et al., 2007; Sellors et al., 2003; Winer et al., 2003).   
Similarly, those who engage in sexual activity with partners who have had three or more 
sex partners are at increased risk of contracting HPV.  This is due to their partner’s 
increased risk of exposure to the virus (Centers for Disease Control and Prevention, 
2007a; Winer et al., 2003).  Other high-risk sexual behavior, such as inconsistent use of 
condoms, increases the risk of exposure to HPV and other STIs (Centers for Disease 
Control and Prevention, 2005; Shew et al., 2006).    
Since many HPV infections are asymptomatic and self-clear, most infected 
women never know they were infected.  The CDC estimates that the body clears 70% of 
new HPV infections within one year and 90% within two years without any medical 
intervention or adverse health outcomes (Centers for Disease Control and Prevention, 
2007a).   Researchers categorize HPV types into high-risk and low-risk groups based on 
the type’s risk of attributing to the development of cervical cancer or other precancerous 
cervical lesions (Centers for Disease Control and Prevention, 2007a).   
 A persistent infection with one or more high-risk HPV types, primarily type 16 
and type 18, can result in cervical cancer or precursor lesions (Munoz et al., 2003).  An 
HPV infection is necessary for the development of cervical cancer and precursor lesions, 
though, it is not always sufficient to cause cervical abnormalities (Centers for Disease 
Control and Prevention, 2007a).  Although the HPV infection is not treatable, cervical 
cancer and precursor cervical lesions are treatable if identified through Pap screening.  
Approximately 11,000 cases of cervical cancer (8.1 per 100,000 women) occur in the 
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U.S. annually.  Roughly 4,000 of these cancer cases result in death each year (National 
Cancer Institute, 2006; Ries et al., 2007).    
 Infections of low-risk types can develop into genital warts; types 6 and 11 are 
associated with approximately 90% of genital warts (Centers for Disease Control and 
Prevention, 2007a).  Healthcare providers can remove genital warts, but the virus may 
persist leading to a reoccurrence of warts (Centers for Disease Control and Prevention, 
2007a).  Unlike other STIs, HPV and genital warts are not reportable to local, state, or 
federal agencies.  Therefore, research estimates must calculate the probable incidence 
rates (Centers for Disease Control and Prevention, 2005).  Since HPV is most often 
asymptomatic and self-clears without detectable adverse events, accurate HPV reporting 
is difficult (Sellors et al., 2003).  Additionally, the estimated HPV related genital warts 
and cervical cancer cases are small when compared with the total number of HPV 
infections (Centers for Disease Control and Prevention, 2007a; Dunne et al., 2007; Myers 
et al., 2000; Weinstock et al., 2004).  Though HPV affects males and females, FDA 
currently licenses Gardasil® only for females.  Therefore, vaccinating females before 
sexual debut is one of the most effective methods for reducing the transmission of HPV 
6, 11, 16, 18 and preventing cervical cancer (Centers for Disease Control and Prevention, 
2007a; Hampl, Sarajuuri, Wentzensen, Bender, & Volkmar Kueppers, 2006).  
 
The HPV Vaccine: Gardasil® 
Merck produces the HPV quadrivalent vaccine, Gardasil®.  The conclusion of the 
Merck HPV vaccine clinical trials demonstrated nearly 100% efficacy rates among 
females against HPV types 6, 11, 16, and 18 (Garland et al., 2007; Shi et al., 2007).   
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When examining clinical study endpoints, the vaccine efficacy against HPV related 
cervical intraepithelial neoplasia (CIN) and adenocarinoma in situ was 95%-100% 
(Garland et al., 2007).  The study also demonstrated 99% vaccine efficacy for HPV 6 and 
11 related genital warts (Zimmerman, 2007).  Follow up studies are planned to determine 
long-term efficacy and safety of the vaccine (Centers for Disease Control and Prevention, 
2007a; Zimmerman, 2007).  Currently, it is unclear if a booster dose will be required to 
maintain immunity.  However, at the 5-year mark, immunological studies showed no 
reduction in protection among the vaccinated population (Garland et al., 2007; Shi et al., 
2007).   
 Vaccine safety and adverse events are generally mild injection-site reactions 
common to other vaccines.  Most reported adverse events are injection-site pain, swelling 
and erythema (Garland et al., 2007).  Long-term safety of the vaccine is still unknown 
since the vaccine is relatively new.  The Vaccine Adverse Event Reporting System 
(VAERS) and the CDC’s Vaccine Safety Datalink monitor the vaccine’s long-term safety 
(Centers for Disease Control and Prevention, 2007a; Iskander, 2007).  Other concerns 
exist regarding the HPV vaccine’s safety.  These include the belief that the vaccine 
reduces routine cervical cancer screenings and encourage unsafe sex practices.  Also, the 
belief exists that the vaccine may encourage promiscuity and increase STI infections 
among young females (Zimmerman, 2007). 
 As noted herein, the FDA license for Gardasil® only permits 9 to 26 year old 
females to receive the vaccine.  Healthcare providers administer the three shot series at 
months 0, 2, and 6.  The ACIP recommended the HPV vaccine for routine use among 
females age 11 and 12, though healthcare providers can administer the vaccine to nine 
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and 10 year olds at a parent’s request.  The ACIP recommends catch-up vaccination 
among females age 13 through 26.  The vaccine is most effective when given before 
sexual debut.  This reduces the chances of previous HPV exposure, which maximizes the 
full benefit of vaccination (Centers for Disease Control and Prevention, 2007a; Garnett, 
2005).   The addition of the HPV vaccine to the immunization schedule makes Gardasil® 
a highly recommended part of the adolescent immunization series.  The recommended 
vaccines on the adolescent immunization schedule are the tetanus, diphtheria, pertussis 
vaccine, meningococcal vaccine, and the HPV vaccine (Centers for Disease Control and 
Prevention, 2007a, 2007c).  A recommendation without a state school entry mandate 
leaves the decision to vaccinate between healthcare providers, parents, and patients.   
 
School Entry Vaccine Mandates 
U.S. laws relating to immunization requirements date back to the early 1900s with 
the Massachusetts universal compulsory smallpox vaccine policy.  In 1905, the Supreme 
Court upheld the right of a state to implement compulsory immunization regulations in 
the interest of public health in Jacobson v. Massachusetts (Jacobson v Massachusetts, 
1905).  Since this time, the Supreme Court constantly supported the right of states to safe 
guard public health through the implementation of school entry vaccine mandates (Evans, 
Harris, & Levine, 2004; Orenstein, Rodewald, & Hinman, 2004).  However, school entry 
vaccine mandates and enforcement did not become institutionalized methods for reducing 
the vaccine-preventable disease burden until the 1970s, when this tactic was shown to be 
helpful in reducing measles outbreaks (Orenstein & Hinman, 1999; Orenstein et al., 
2004).   
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 The effectiveness of school entry vaccine mandates in increasing and maintaining 
high immunization coverage rates necessary to decrease disease among school and 
daycare age groups is evident with other vaccine-preventable diseases (Dailard, 2006; 
Orenstein & Hinman, 1999).  In an analysis of adolescent Hepatitis B vaccine coverage 
rates, Wilson and Fishbein, et al. found that ninth graders in states with Hepatitis B 
school entry mandates had coverage rates of 72%, while only 18% of ninth graders were 
vaccinated for Hepatitis B in states without such mandates (Wilson, Fishbein, Ellis, & 
Edlavitch, 2005).  Another analysis of Hepatitis B and Varicella vaccine coverage among 
insured adolescents across 28 states found significantly higher coverage rates among the 
adolescents of states where state mandates for these vaccines were in place (Olshen, 
Mahon, Wang, & Woods, 2007).   
 The high vaccine coverage for childhood vaccine-preventable diseases and a 
reduction of health disparities among school-aged children in the U.S. is directly 
attributable to school entry vaccine mandates (Dailard, 2006; Hinman, 2003; Orenstein & 
Hinman, 1999; Stewart, 2007a, 2007b).  For this reason, school entry vaccine 
requirements are “safety net” policies since the regulation improves vaccine coverage 
levels among the minority and disadvantaged children, thus reducing the vaccine-
preventable disease burden among these children (Institute of Medicine, 2003; Orenstein 
& Hinman, 1999). 
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School Entry Vaccine Mandates: a State Perspective 
States determine school entry vaccine mandates through regulatory and legislative 
actions.  Vaccine mandates exist in all 50 states, but vary from state to state, though 
mandates for more communicable diseases are typically standard (Centers for Disease 
Control and Prevention, 2006; Evans et al., 2004; Institute of Medicine, 2003; Orenstein 
& Hinman, 1999; Stewart, 2007a).  Nearly all states require proof of vaccination against 
diphtheria, measles, rubella, polio, tetanus, and pertussis for school entry. (Centers for 
Disease Control and Prevention, 2006; Orenstein & Hinman, 1999).   
All 50 states offer exemptions from school entry mandates, though the allowable 
categories of exemption vary depending on state regulations and law.  There are three 
categories of exemptions: medical, religious, and philosophical.  All states offer medical 
vaccine exemptions to excuse individuals from receiving the mandated vaccine if a 
healthcare provider determines the vaccine may pose a medical danger to the person’s 
health (Orenstein et al., 2004).  Most states (48) offer religious exemptions to excuse 
individuals from vaccination due to a conflict in religious belief.  Only a few states (15) 
offer philosophical exemptions for immunizations, whereby those who are 
philosophically opposed to vaccination are exempt from the vaccine mandate (Centers for 
Disease Control and Prevention, 2006; Orenstein & Hinman, 1999; Orenstein et al., 
2004).  Exemption requirements vary from state to state in terms of the public burden of 
filing for an immunization exemption.  Some states require official forms signed by a 
parent while others only require a simple letter of objection (Orenstein et al., 2004).   
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Vaccine Financing Mechanisms 
Vaccine program funding comes from federal and state sources.  The federal 
government established two sources of vaccine financing mechanism to aid in increasing 
immunization coverage rates in the U.S.  These funding sources are Vaccines for 
Children (VFC), a federal entitlement program, and the 317 Grants, a federal grant 
program that receives direct annual funding from Congress (Institute of Medicine, 2003; 
Orenstein et al., 2004).  In addition, states allocate funds to immunization programs as 
part of the regular state budgetary process.   
VFC funds account approximately 43% of vaccine expenditures (Lee et al, 2007).  
The federal VFC program was established in 1994 to provide free immunization services 
to uninsured children at their regular healthcare provider (Institute of Medicine, 2003).  
VFC provides vaccines for qualified children to private providers and provides free 
vaccines to children at Federally Qualified Health Centers (FQHC) and Rural Health 
Clinics (RHC).  Children less than 19 years of age and either uninsured, Medicaid-
eligible, or of Alaskan/American Indian decent are considered eligible for VFC.  
Additionally, underinsured children less than 19 years old are VFC eligible when 
vaccinated at a FQHC or RHC (Centers for Disease Control and Prevention, 2007b; 
Institute of Medicine, 2003; Orenstein et al., 2004).  Once the ACIP adds a vaccine to the 
recommended childhood/adolescent immunization schedule and votes to include the 
vaccine for use under the VFC program, the vaccine must be subsidized under VFC for 
qualified children (Orenstein et al., 2004).  The CDC negotiates federal contracts with 
vaccine manufacturers for VFC vaccines and states, in turn, order the vaccines at the 
CDC negotiated purchase price (Institute of Medicine, 2003). 
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The 317 funding is part of the Public Health Service Act of 1972, which was 
designed with the purpose to assist state immunization programs build and maintain 
vaccine infrastructure as well as purchase vaccine (Institute of Medicine, 2003).  
Additionally, the 317 Federal Grant provides states with funds, which are often used to 
vaccinate children who are not VFC eligible, particularly underinsured children seeking 
immunization services.  However, federal 317 Grant reductions over the past decade have 
placed substantial strain on states to contribute more to finance immunization programs 
(Freed, Clark, & Cowan, 2000; Lee et al., 2007).  The growing cost of fully vaccinating 
the increasing number of underinsured children, compounded with a reduction in 317 
Grant funding and an increase in number of new, expensive vaccines on the 
immunization schedule, there are many financial challenges facing state immunization 
budgets (Institute of Medicine, 2003; Lee et al., 2007).  Disparities in vaccination 
coverage rates are emerging between VFC-eligible (uninsured) and VFC-ineligible 
(underinsured) children, particularly with newer vaccines (Lee et al., 2007).   
Private funding for immunization services is another method through which many 
children receive immunization services.  Private funding accounts for approximately 46% 
of vaccine purchase and vary depending on insurance status and insurance benefits 
coverage (Lee et al., 2007).  Private vaccine financing occurs when either the family, 
insurance company, or combination of both funds the cost of immunizing a child.  When 
a child has insurance coverage for recommended vaccines, the insurance company 
reimburses the provider or the family for some or all of the vaccine cost.  When the child 
is underinsured (has insurance coverage but immunization services are not a covered 
benefit) the family is responsible for the cost of vaccination, except in states that provide 
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funding mechanisms for those children.  Since the number of underinsured children in the 
U.S. is growing, the financial strains of covering vaccination of underinsured children 
have increased.  Many states have passed legislation to require insurance companies to 
cover immunization services (Freed et al., 2000; Institute of Medicine, 2003; Lee et al., 
2007).    
Through March of 2007, 16 states have proposed compulsory insurance coverage 
of the HPV vaccine specifically (National Conference of State Legislatures, 2007).  
However, compulsory insurance coverage of the HPV vaccine does not automatically 
define the terms for which children can receive the vaccine.  For instance, insurance 
companies can still require increased monthly premiums, deductibles, and co-pays to 
offset the costs associated with mandated vaccine coverage.  In this manner, the 
insurance companies can still pass the cost on to the patient, creating more barriers for 
vaccination (Institute of Medicine, 2003; Lee et al., 2007).    
 
HPV Vaccine: Costs v. Benefits 
According to the CDC Vaccine 2007 Price List, the cost of the HPV vaccine per 
dose is significantly higher than other recommended vaccines (Centers for Disease 
Control and Prevention, 2007c, 2007d).  Figure 1 illustrates the cost differential between 
the HPV vaccine and other recommended vaccines.  As shown, the private sector and 
VFC cost of the HPV vaccine per dose ranges between $65 and $100 more than other 
vaccines, except for the Meningococcal vaccine, which is $30 less.  Both Meningococcal 
vaccine and HPV vaccine cost more than older vaccines, primarily because both vaccines 
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are newly created medical innovations (Centers for Disease Control and Prevention, 
2007d). 
Figure 1.  Vaccine Cost Per Dose 
Vaccine Cost Per Single Dose, 2007
$0 $20 $40 $60 $80 $100 $120
Hepatitis  A
Hepatitis B
Measles Mumps & Rubella
Tetanus
Meningococcal
Human Papillmavirus
Cost Per Single Dose in U.S. Dollars
Private
Sector
CDC/VFC
Table generated from CDC Vaccine 2007 Price List (Centers for Disease Control, 2007d)
Public 
Sector
 
 
The cost of the vaccine in relation to HPV vaccine related diseases is an important 
factor when evaluating policy implications of vaccine mandates.  The estimated cost of 
treating and preventing HPV related diseases in the U.S. is approximately $5 billion 
annually (Insinga, Dasbach, & Elbasha, 2005).  Mathematical models predict that 
vaccination of adolescent females against HPV will be cost-effective only after achieving 
high coverage rates, i.e., over 70 percent coverage (Elbasha, Dasbach, & Insinga, 2007; 
Goldie et al., 2004).  The Goldie et al. model for an HPV 16/18 protective vaccine shows 
 16 
 
an increased economic cost-benefit ratio when high coverage rates exist and cervical 
cancer screenings decrease from annually to once every three years (Goldie et al., 2004).  
However, the Elbasha model, which includes the four HPV types (6/11/16/18) in 
Gardasil® is cost effective with annual cervical cancer screenings, which is the current 
recommended strategy of the ACIP (Centers for Disease Control and Prevention, 2007b; 
Elbasha et al., 2007).  The high coverage rate required for cost effectiveness further 
strains state vaccine budgets. 
 When states implement a widespread vaccination strategy, the vaccine cost 
combines with the cost of treatment, creating a larger financial burden for the state.  This 
burden of double payout for both prevention and treatment of HPV continues until the 
falling number of treatments reduces the cost to such a point that the vaccine strategy 
costs less than the cost of treating HPV related diseases (Miller & Hinman, 2004).  After 
this crossing point, the costs decrease below the pre-vaccination treatment payout. 
 
HPV Vaccine: The Debate  
A school mandate for HPV vaccination of sixth-grade females is likely to be an 
effective tool to increase vaccination coverage in this population.  The anticipated results 
of high coverage may conceivably decrease HPV 6, 11, 16, and 18 rates and eventually 
reduce national cervical cancer incidence (Elbasha et al., 2007; Garnett, 2005; Orenstein 
& Hinman, 1999).  Without a mandate, there will likely be health disparities in HPV 
vaccination coverage between those with access to the vaccine and those without 
(Stewart, 2007).  However, there are many aspects of HPV vaccination mandates that 
create opposition among some groups.   
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 Much of the editorial and media reported concern centers on relation to parental 
rights, vaccination mandates, and adolescent sex (Charo, 2007; Gibbs, 2006; Moreno, 
Berger, & Singer, 2006; "A necessary vaccine [Editorial]," 2007; Stewart, 2007; The 
Associated Press, 2007).  The concern expresses two main themes: first, whether parents 
or the government should determine when and if an adolescent receives HPV vaccine, 
and secondly, whether a reduction in the risk of HPV will modify adolescent sexual 
behaviors. 
Since a person can contract HPV only through sexual, rather than casual contact, 
a debate exists surrounding the state’s right to mandate versus the parents’ right to raise 
their children in a manner they see fit (Gibbs, 2006; Moreno et al., 2006; Stewart, 2007; 
Associated Press, 2007).  Traditionally, state governments mandate vaccines to prevent 
the spread of highly infectious diseases.  Therefore, state mandates provide positive 
consumption externalities, such as herd immunity (Institute of Medicine, 2003).  Thus, 
HPV vaccine school entry mandates step outside the norm of policy precedent and some 
parents oppose government mandate of the vaccine (Gibbs, 2006; Stewart, 2007a, 
2007b).  In addition, some parents think vaccinating 11 and 12 year olds for an STI is too 
early due to the belief that sex does not occur the mid- to late- teenage years (Gibbs, 
2006; "A necessary vaccine [Editorial]," 2007).   
Some conservative groups, such as the Family Foundation, Family Research 
Council, and Focus on the Family, fear that a preventive HPV vaccine will condone and 
promote promiscuity among adolescents.  By vaccinating their adolescent daughters, 
some fear they will be sending their daughters the message premarital sex is acceptable, 
which contradicts the “abstinence until marriage, fidelity in marriage only” message 
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(Charo, 2007; Gibbs, 2006; Moreno et al., 2006; “A necessary vaccine [Editorial], 2007; 
Associated Press, 2007.  However, there is no empirical evidence to suggest that the HPV 
prophylaxis vaccine will increase sexual activity among adolescents (Monk & Wiley, 
2006).  Regardless of empirical evidence, several groups support HPV education and 
voluntary vaccination programs instead of a school entry mandate (Gibbs, 2006; "A 
necessary vaccine [Editorial]," 2007; Associated Press, 2007; Wilson, 2007). 
Some of the controversy surrounding the HPV vaccine is in response to the 
actions of the pharmaceutical manufacturer, Merck.  When the ACIP recommended 
Gardasil®, they instructed Merck not to engage in lobbying activities that would promote 
school entry mandates for the vaccine.  Jon Abramson, ACIP chair explains: “HPV 
vaccinations should not be mandated because HPV is not a contagious disease and also 
because states have not shown that the funds are available to vaccinate every child 
(Lopes, 2007).”  Since a vaccine mandate would generate substantial revenue for Merck, 
Merck began an aggressive lobbying campaign to mandate the vaccine at the state level.  
Merck started funneling funds to the non-profit advocacy group, Women in Government 
(WIG), to assist in lobbying (Allen, 2007; McGee & Johnson, 2007; Wilson, 2007; 
Wynia, 2007).  Some WIG annual conference participants claimed that WIG’s 
conference educational material and agenda centered on Merck’s agenda to encourage 
vaccine mandates.  In addition, WIG recruited female lawmakers to gain greater 
influence on state legislation to pass HPV vaccine school entry mandates (Allen, 2007; 
Wilson, 2007; Wynia, 2007).  In an interview with National Public Radio, Merck medical 
director Richard Haupt explained Merck supported state vaccine mandates because they 
increase vaccine coverage and “…reach under-served populations, certain ethnic and 
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socio-economic groups that wouldn't be reached otherwise… (Wilson, 2007).”  By late 
February of 2007, Merck agreed to stop its lobbying campaign and focus solely on 
marketing and education (Allen, 2007; Lopes, 2007).    
 
Diffusion Of Innovations 
In his quintessential work, Diffusion of Innovations, sociologist Everett Rogers 
describes the process by which individuals and social groups adopt innovations.  Rogers 
describes the diffusion of an innovation as “process by which (1) an innovation (2) is 
communicated through certain channels (3) over time (4) among the members of a social 
system (Rogers, 2003).”  The basic Rogers Diffusion of Innovation model is a 
multidisciplinary theory used to describe the diffusion of many types of innovations.  For 
the purpose of this study, the general Diffusion of Innovations will be discussed along 
with medical and political diffusion as it relates to the HPV vaccine. 
 
The Population of Diffusion 
In studying the process of innovation diffusion, Rogers discovers the existence of 
distinct sub-groups in a population.  The innovators are the first to adopt an innovation.  
They typically hold higher socio-economic status and are more capable of weathering the 
result of a poor innovation than those in the other groups (Rogers, 2003).  Innovators are 
generally more educated and better adapted to understand and apply complex concepts.  
Innovators are seen as pioneers, risk takers who cope well with uncertainty (Rogers, 
2003). 
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 The second subgroup to adopt an innovation, the early adopters, is more 
integrated in the social network than the innovators.  Rogers states, “The early adopter is 
respected by his or her peers, and is the embodiment of successful, discrete use of new 
ideas.”  As such, the early adopters have the greatest concentration of opinion leaders, 
group leaders whose opinions influence the actions of their affiliated groups.  This group 
is often the primary target for marketing campaigns, as the influence of the opinion 
leaders determines the adoption of an innovation by the general population (Rogers, 
2003). 
 The early majority comprises one of the largest subgroups of the population.  The 
early majority typically adopts an innovation just before the average member.  While 
seldom possessing positions of opinion leadership in the population, their interpersonal 
connections act as a catalyst to continue innovation diffusion.  In deciding to adopt an 
innovation, the early majority tends to deliberate, adopting slower than the innovators and 
early majority, but faster than the remaining groups (Rogers, 2003). 
 The fourth group to adopt an innovation is the late majority.  The late majority are 
nearly as large as the early majority.  Unlike the internal deliberation of the early 
adopters, late adopters feel the weight of peer pressure to adopt an innovation.  The 
skepticism and cautious attitude of the late majority usually means that adoption occurs at 
the risk of financial necessity (Rogers, 2003). 
 The last to adopt an innovation, the laggards, have the longest decision process 
time.  They are typically suspicious of any innovation, as their socio-economic standing 
usually limits their resources available.  Isolated from the majority of the population, this 
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group never holds positions of opinion leadership.  As a result of their “slow to change” 
temperament, other subgroups use the laggards as a point of reference to the past when 
referring to innovation (Rogers, 2003). 
 
Innovation Attributes and Adoption Rates 
 
 The rate of adoption, or the “speed with which an innovation is adopted by 
members of a social system,” determines how quickly an innovation should reach 
maximum adoption (Rogers, 2003).  Since the perceived attributes of the innovation 
guide the innovation decision process, the perceived attributes of an innovation play an 
important role in how quickly, or slowly, an innovation will be adopted.  Rogers outlines 
a number of attributes that act as independent variables that affect the rate of adoption:  
relative advantage, compatibility, trialability, and observability (Rogers, 2003).   
 Relative advantage speaks to cost-benefit of the innovation over the current 
method.  According to Rogers, “Diffusion scholars have found relative advantage to be 
one of the strongest predictors of an innovation’s rate of adoption (Rogers, 2003).”  He 
notes: 
Subdimensions of relative advantage include economic profitability, low 
initial cost, a decrease in discomfort, social prestige, a saving of time and 
effort, and immediacy of reward. This latter factor explains in part why 
preventive innovations generally have an especially slow rate of 
adoption…. A preventive innovation is a new idea that an individual 
adopts now in order to lower the probability of some unwanted future 
event.  Examples are stopping smoking… getting inoculations against 
disease… and adopting contraceptive methods.  The relative advantage of 
preventive innovations is difficult for change agents to demonstrate, 
because the advantages occur at some future and unknown time, and may 
not happen at all.  Thus the relative advantage of preventive innovation is 
highly uncertain. (Rogers, 2003) 
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However, it is important to denote the difference between scientific findings and personal 
experience.  While scientists can empirically prove, for example, a vaccine is efficacious, 
only deliberate, direct known exposure can prove efficacy for an individual.  For 
example, Coleman’s findings on Tetracycline diffusion among doctors found that 
“teaching at the expert level cannot substitute for the doctor’s own testing of the new 
drug…. (Coleman, Katz, & Menzel, 1966).”  Additionally, policy diffusion among states 
has been shown to diffuse by state lawmakers observations of other states that have 
enacted similar policy, rather than information alone (Walker, 1969).  The relative 
advantage is the perceived relative advantage, and not necessarily the documented 
advantage.   
 The next greatest factor in the rate of adoption is Compatibility.  “Compatibility,” 
according to Rogers, “is the degree to which an innovation is perceived as consistent with 
the existing values, past experiences, and needs of potential adopters (Rogers, 2003).  As 
the innovation more closely matches the social-cultural values and beliefs, previously 
held ideas, and the need for the innovation, the rate of adoption increases (Rogers, 2003).  
If a state adopts a policy, then the policy is more likely to diffuse to bordering states with 
similar ideological characteristics than bordering states with different ideological 
characteristics (Grossback, Nicholson-Crotty, & Peterson, 2004; Walker, 1969) 
 However, complexity is inversely proportional to rate of adoption; the more 
complex the innovation is to understand and implement, the slower it will be to adopt.  
Complexity is not as grave a determining factor as relative advantage or compatibility, 
though it still can play a vital role in some innovations (Rogers, 2003). 
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Trialability, the ability for an individual to use the innovation on a limited, 
noncommittal basis, gives the individual to test to see if the innovation does meet the 
needs in a beneficial manner.  Trialability is more important to earlier adopters, like 
innovators and early adopters, because there is a lack of precedent set for true results 
among peer usage.  Trialability becomes less important as more people in the social 
network use the innovation, as “trial by proxy” increases (Rogers, 2003).  The more an 
individual is capable of trying out an innovation, the more likely the innovation will have 
a higher rate of adoption (Rogers, 2003).  States also follow this pattern of diffusion by 
watching the actions and results of policy adoption in other states and then either 
adopting or rejecting the policy.  Most often, states will adopt policies adopted that have 
been adopted by other states, particularly neighboring states (Grossback et al., 2004; 
Mooney, 2001; Walker, 1969). 
 Finally, “Observability” according to Rogers, “is the degree to which the results 
of an innovation are visible to others.”  Innovations that have observability that is more 
concrete are more likely to have a higher adoption rate (Rogers, 2003).  
 
The Consequences of Innovating 
 Rogers recognizes the consequences or changes that occur when an individual 
chooses to adopt an innovation are not merely the intended effects of the innovation.  
Rogers states, “We find it useful to analyze three dimensions of consequences: (1) 
desirable versus undesirable, (2) direct versus indirect, and (3) anticipated versus 
unanticipated.”  Rogers generalizes that, “The undesirable, indirect, and unanticipated 
consequences of an innovation usually go together, as do the desirable, direct, and 
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anticipated consequences.”  This means that the innovation’s intent demonstrates, and the 
adopter’ expectations require, that the anticipated results from the innovation’s direct use 
are desirable.  However, the undesirable consequences are frequently an indirect and 
unanticipated result of adoption.  Moreover, a “principle of inseparability” exists, where, 
as Rogers writes, “The effects of an innovation usually cannot be managed so as to 
separate the desirable from the undesirable.” 
One of the difficulties in speaking of consequences is the subjectivity 
involved.  By assigning desirable or undesirable, for example, the 
individual must make a value-based judgment (Rogers, 2003).  This 
subjective judgment may not be understood between social groups, 
resulting in an undesirable consequence for one group, while another sees 
a desirable consequence.  One example, as Rogers outlines, is the case of 
the Old Order Amish. Rogers writes, They willingly forgo the advantages 
of tractors and modern farm equipment (such as larger farms, higher crop 
yields, and increased income) in order to avoid the undesirable 
consequences of increased dependence on non-Amish businesses (such as 
farm machinery dealers), lessened farm labor requirements, and the 
pressure for larger-sized farms. (Rogers, 2003) 
 
Naturally, the characteristics of the innovation and the social group in which diffusion 
takes place help determine how quickly the innovation will be adopted.  In policy actions, 
if the policy adoption may influence election results, lawmakers will likely consider the 
desired effect of their judgment on voter satisfaction (Grossback et al., 2004). 
 
Preventive Innovations 
Preventive Innovations can be incredibly slow to adopt.  Since their relative 
advantage is only measurable in the distant future under theoretical circumstances, the 
reward for innovating is delayed.  Moreover, depending on circumstances of the 
individual, the reward may be thwarted by some other external force.   Given that the 
 25 
 
result of preventive innovations, like vaccines, is a nonevent, the proof that the 
innovation works is impossible to contrive in real-time.  As with the case of disease, 
infection is exposure nearly always determined by contraction (Rogers, 2003). 
 In certain cases, the relative advantage is so low that the change agents must offer 
individuals incentives to adopt the innovation.  Incentives, which are direct or indirect 
monetary benefits for adopting, often change the behaviors of certain groups.  For 
example, Rogers finds “When a relative adopter incentive is paid to family-planning 
adopters, for example, individuals of the lowest socioeconomic status adopt.”  As 
discussed earlier in this chapter, programs fund free or subsidized vaccines to lower 
socioeconomic groups, such as the VFC, 317 Grants, and state vaccine funding.  These 
free and discounted vaccine services encourage earlier vaccine adoption from lower 
socioeconomic populations that might otherwise be incapable of adopting (Rogers, 2003).  
Alternatively, when the public’s health is of concern, governments can mandate 
an innovation.  When a government chooses to mandate an innovation, the government 
artificially increases the relative advantage for adopting the innovation (Rogers, 2003).  
The net result is that the individual perceives a greater relative advantage for innovating 
and chooses to adopt to remain in compliance with the law. 
 
HPV Vaccine through the Diffusion of Innovation Lens 
HPV vaccine is a preventive innovation, in that Merck created Gardasil® to 
prevent cervical cancer and genital warts; Gardasil® addresses the empirical need to 
reduce the infection rates of HPV and HPV-related diseases. Policymakers across the 
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country are considering laws and policy to adopt mandates and funding for the HPV 
vaccine.  According to the Diffusion of Innovation theory, Gardasil®’s low relative 
advantage, incompatibility with some beliefs, lack of trialability, and lack of 
observability make the vaccine less capable of integrating easily into the population and 
state as an adoptable innovation (Rogres, 2003).  The relative advantages of the 
innovation are low due to the high cost of the vaccine and the existing funding strain on 
state immunization programs.  Given the relatively low “immediacy of reward” for 
adopting the innovation, state populations and lawmakers may find that adopting the 
innovation yields few, immediate results (Grossback et al., 2004; Rogers, 2003).  Since 
the vaccine will take several years to yield maximum results, reducing the incidence of 
HPV related disease, HPV policy’s positive externalities will also take years to show the 
full effect. 
Additionally, state policymakers risk alienating voters that disagree with HPV 
vaccine policy due to the incompatibility of the innovation with the voters’ beliefs.  
Given the disease transmission route (sexually rather than casually), some parents and 
special interest groups oppose widespread adoption.  The vaccine is thought to conflict 
with the abstinence before marriage message supported by social conservatives.  Other 
obstacles to adoption are the fear that a preventive vaccine will change sexual behaviors 
of adolescents (Charo, 2007; Gibbs, 2006; "A necessary vaccine [Editorial]," 2007; 
Associated Press, 2007; Wilson, 2007).  These public concerns may influence the policy 
actions of state elected representatives that will require continued voter support to retain 
his or her elected position through the next election cycle. 
 The preventive nature of this new innovation can influence policy actions taken 
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across states.  Vaccines, as a preventive innovation, are different from other innovations 
since they lack direct trialability and observability (Rogers, 2003).  Individuals cannot try 
a vaccine prior to full adoption; one must fully adopt or reject of the vaccine from the 
onset.  If an individual accepts a vaccine, that person must willingly accept all the 
consequences of adoption outright.  Finally, observability is difficult because one cannot 
absolutely prove a benefit without known exposure.  Moreover, no one is likely to 
intentionally challenge his or her own disease immunity.   
 The HPV vaccine has been on the market for under two years and policy related 
to HPV is new.  Newness alone can contribute to slow policy adoption.  Mooney explains 
the slow nature of new policy diffusion as well as the influence of trialability;  
Early in a diffusion, little information is available to help policymakers 
reduce uncertainty in decision making. The policy may be untested and its 
long-term consequences unknown. Having the policy recently adopted by 
a neighbor increases the information available about both its policy and 
political consequences. (Mooney, 2001) 
 
As policy options diffuse through states, the increasing acceptability of HPV policy 
options increases.  Additionally, the intervention cost-benefit is examined in relation to 
the state economic characteristics to assess economic feasibility of adopting the policy 
(Karch, 2006).  HPV funding allocation has to be a feasible economic option for diffusion 
of the policy to have a greater relative advantage.  
 
The Groups of Innovators 
The voting population of a state generally can be divided into party affiliation.  
The Pew Research Center’s population survey reports identify these party affiliations and 
their self-reported ideological beliefs.  The political platform of Republicans (social 
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conservatives) is traditionalist, pro-family, rooted in morality and a conservative belief 
structure (Pew Research Center, 2006a, 2006b).  This platform of conservative, social 
ideology may make them less likely to adopt an innovation whereby children can more 
freely choose to engage in sexual behaviors.  The conservative, traditional beliefs held by 
the Republicans may be incompatible with the belief that an HPV vaccine should be 
required.  The result of the conflict of beliefs could result in a delayed adoption of the 
vaccine by Republicans.  The structure of this paper theorizes that Republican-controlled 
states, as defined in Chapter III, will be less likely to adopt mandate or funding incentives 
to ensure the vaccine reaches large numbers of children.    
 The political platform of Democrats (social liberals) is more moderate on social 
issues such as family structures, premarital and safe sex, and healthcare according to the 
Pew Research Center reports (Pew Research Center, 2006a, 2006b).  The Democratic 
platform is more likely to support policy which encourages safe sex practices over 
abstinence only.  The Democratic belief structure could be said to be more compatible 
with the beliefs required to adopt an HPV vaccine mandate.  Thus, states controlled by 
Democrats, as defined in Chapter III, are more likely to accept new preventive 
innovations, mandates, and funding incentives to encourage vaccine adoption, such as 
mandating Gardasil®. 
 
Policy as Adoption 
Mandates are negative incentives.  Through mandates, states ensure population 
adoption by restricting non-compliant individuals from using state government programs 
and services, such as the public school system (Evans, Harris, & Levine, 2004; Orenstein, 
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Rodewald, & Hinman, 2004).  In the case of school entry required vaccines, punishments 
for non-compliance without proper documentation vary from state to state (Orenstein et 
al., 2004).  In November 2007, the state of Maryland ordered parents of 2,300 students to 
court in an effort to ensure compliance of the state vaccine mandates.  Their punishments 
varied from immediate compulsory vaccination of the student to fines or the arrest and 
detention of the students’ parents in the Maryland penal system.  The results of the 
Maryland mandate crackdown included 1,400 correctly immunized students and a host of 
upset parents (Kuchment, 2007; Manning, 2007). 
Rather then restricting individuals from using government programs, funding 
mechanisms offer the positive incentive of free or reduced-cost vaccine services to 
influence voluntary adoption.  By subsidizing vaccines, a government encourages 
adoption by raising the relative advantage, since a reduction in cost at the individual level 
increases the cost-effectiveness (i.e. relative advantage) of innovating (Rogers, 2003).  
Moreover, when combined with a mandate, funding ensures compliance for those in 
lower socio-economic groups.   
 
Summary 
As discussed earlier, HPV is the most prevalent STI, and is associated with 
cervical cancer and genital warts (Centers for Disease Control and Prevention, 2007a; 
Weinstock, Berman, & Cates, 2004).  In response to this growing threat, Gardasil® 
quadrivalent HPV vaccine was introduced to address the cancer and warts associated with 
HPV.  As an innovation that addresses a prevalent disease, many politicians have 
attempted to encourage adoption of this vaccine, either through mandate or funding 
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(National Conference of State Legislatures, 2007). 
Past court rulings have held that states have the right to mandate vaccines in the 
interest of public health.  Traditionally, these vaccines covered diseases that were highly 
contagious and casually communicable (Evans, Harris, & Levine, 2004; Jacobson v 
Massachusetts, 1905; Orenstein, Rodewald, & Hinman, 2004).  HPV, as a disease, varies 
from previously mandated diseases in that HPV requires direct genitalia contact between 
two people and is not casually communicable (Centers for Disease Control and 
Prevention, 2007a).  This variance has sparked critical debate between social liberals 
(Democrats) and social conservatives (Republicans), where social liberals tend to side in 
favor of mandate, while social conservatives tend to argue against mandate. 
As an innovation, Gardasil® can be observed to diffuse among a population.  Its 
characteristics lend itself toward potentially having a long decision period prior to 
adoption.  Its preventive nature, high cost, and unknown, unintended societal 
consequences create a low relative advantage that will likely make the adoption process 
slow. 
Since adoption at the individual level is much more difficult to observe, 
observance at the state level can produce quantifiable results with easy to interpret 
comparisons between social liberals and social conservatives through party affiliation of 
elected representatives (Grossback et al., 2004; Mooney, 2001; Walker, 1969).  Through 
proposing or passing legislation that mandates or provide funds for the HPV vaccine, 
states can be said to adopt the innovation through the actions of the elected 
representatives. 
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CHAPTER III 
 METHODOLOGY 
 
To test the hypothesis (H1) that there is an association between mandating use of 
or funding for the HPV vaccine and such variables as state health and political 
characteristics (for the time period studied), logistic regression analyses were conducted 
using SPSS.  The data used for this research was secondary, quantitative data collected on 
state proposed and enacted mandated use of and funding for the HPV, as well as potential 
influencing state factors.   These potential influencing factors are state health and political 
characteristics.  Odds ratios were used to evaluate the associations between the 
independent and dependent variables using a statistical significance level 0.05.  The data 
used for state health and political characteristics was the most recent data available in 
March of 2007.  The sources of the data will be discussed by variable below. 
 
Independent Variables 
The state health characteristics (independent variables) used in this study are state 
cervical cancer incidence rates per 100,000 women, Pap smear screening percentage, 
percentage of uninsured women by state, and United Health Foundation state health 
score.  The state political characteristics (independent variables) in this study are state 
legislative political control (Democrat majority of state legislature, Republican majority 
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of state legislature, or House and Senate controlled by different parties) and gubernatorial 
political party affiliation.   
Cervical cancer incidence rates by state were collected from the 2005 Centers for 
Disease Control State Cancer Registry and the National Program of Cancer Registries 
Cancer Surveillance System (National Cancer Institute, 2006).  The most current state 
level cervical cancer age-adjusted incidence rates (between 2003 and 2004) for all 
females were utilized.  These invasive cervical cancer rates were calculated by CDC 
using SEER*Stat, a statistical software used for studying cancer, and reported on the 
National Cancer Institute State Cancer Profile (National Cancer Institute, 2006).   
Pap screening percentages were collected from the CDC’s 2004 Behavioral Risk 
Factor Surveillance System (BRFSS) Data.  The BRFSS is the largest phone health 
survey which is conducted annually on a variety of health issues across all 50 states and 
U.S. territories (BRFSS, 2007).  The BRFSS 2004 surveyed U.S. women over 18 years of 
age to determine the percentage of women who have had a pap screen in the last three 
years by state (Women's Health, 2007).   
The Kaiser Family Foundation analysis of the insurance status for women ages 19 
to 64 by state reported the percentage of uninsured women, which was utilized for the 
variable “uninsured women” in this study.  The Kaiser Family Foundation based its 
report on insurance status on data collected from the Census Bureau’s 2006 and 2007 
Current Population Survey (Health Insurance Coverage, 2006).   
The National Governors Association (NGA) report entitled Governors of the 
American States, Commonwealths and Territories was used for the source of the political 
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affiliations of governors for each state (Governors: The American States, 
Commonwealths, and Territories, 2007).  The NGA is a non-partisan organization of 
governors that provides education, support, collaboration forums, and advocacy.  
Gubernatorial party affiliation identifies the state governor’s political affiliation as 
reported by the National Governors Association: Republican, Democrat, or other.   
The state legislative composition of the state legislatures is reported by the 
National Conference of State Legislatures (National Conference of State Legislatures, 
2006).  The state legislative composition was reviewed to determine the political party 
control of the two chambers of a state legislature.  In cases were one party controls both 
chambers, the legislature majority control was assigned to the controlling political party.  
When the Republican Party controls one chamber and the Democratic Party controls 
another, the legislative majority is determined to be split.  Any outlying political power 
distribution where political control differs from these two dominant scenarios, such as 
one chamber is controlled by one party and the other has no clear dominating party, the 
variable determined mixed.   
United Health Foundation (UHF) is a non-profit, private foundation based in 
Minnetonka, Minnesota.  The UHF assigns scores to states based on numerous health 
factors in its annual assessment America’s Health Rankings: A Call to Action for People 
& Their Communities (United Health Foundation, 2006).  The health factors used to 
evaluate the overall health fall into the following categories:  
• Personal behaviors - prevalence of smoking, motor vehicle heaths, 
prevalence of obesity, high school graduation rate; 
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•  Community environment - violent crime, occupational fatalities, 
infectious disease, children in poverty; 
• Public health and health policies - lack of health insurance, per capita 
public health spending, immunization coverage; 
• Health services - adequacy of prenatal care, quality of care, cost 
efficiency; and 
• Health outcomes - poor mental health/physical health days, infant 
mortality, cardiovascular deaths, cancer deaths, premature deaths. 
The 2006 overall state health score was used as an indicator of overall state public health.  
This score assigned based on numerous health factors.  The national average (0) is 
considered the baseline and scores are determined to have a positive or negative score 
based on its health factors in comparison to the national average (United Health 
Foundation, 2006).   
 
Dependent Variables 
 
The dependent variables were HPV vaccine school entry mandates proposed or 
enacted, and vaccine funding legislation with funds earmarked for HPV vaccine or 
general funding increases to vaccine programs proposed or enacted.  The source of the 
HPV vaccine school entry mandate variable was from data reported by the Women in 
Government (WIG) in its state activity policy update, Women in Government Challenge 
to Eliminate Cervical Cancer Campaign State Activity, Activity as of March 17, 2007 
(Women in Government, 2007a).  WIG is a non-profit, bi-partisan association of elected 
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women lawmakers which specializes in education and networking.  It is a comprehensive 
source of standardized state level political HPV vaccine actions. 
The HPV vaccine funding variable data were reported by the National Conference 
of State Legislatures (NCSL) on its website under State and Federal Issues: HPV Vaccine 
2007 tracking, which was updated March 2007 (National Conference of State 
Legislatures, 2007).  This site provides updates from each state’s legislative session.  
NCSL is a non-profit, bi-partisan organization that offers state and territorial legislative 
bodies research, education, advocacy, and collaborative assistance.  The NCSL HPV 
report offered a standardized, cross-sectional view of state legislative action(s).  Without 
this overview of state legislative activity, data would have to have been collected from 
each state’s legislative body.   
Given the difficulty of measuring individual adoption of the innovation, elected 
officials serve as proxy for the general population they represent for this study.  Since 
elected officials can be divided by political party (except in the Nebraska legislature) a 
study can determine if a correlation exists between an elected political majority of a state 
and the decision of that state to adopt the vaccine (Adams, 2006; National Conference of 
State Legislators, 2006).  For the purpose of this paper, elected officials demonstrate 
state-wide adoption through proposing or passing a HPV vaccine mandate or through 
proposing or passing a HPV vaccine funding bill.  As such, HPV vaccine school entry 
mandates and HPV vaccine funding symbolize vaccine policy adoption.   
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Variables and Diffusion of Innovations 
  The Diffusion of Innovations concepts of relative advantage, compatibility, and 
adoption have direct application in this study.  For example, the independent variable of 
state health characteristics utilized in this study can demonstrate the relative advantage of 
a state adopting HPV mandates or funding.  The independent variable of state political 
characteristics demonstrates the compatibility of the vaccine policy adoption.  As 
discussed in Chapter II, the social liberals may be more likely to adopt the innovation 
than social conservatives because social conservative beliefs vary from the beliefs 
required to adopt the vaccine voluntarily. The two-party system of American politics, 
Republicans (social conservatives) and Democrats (social liberals), easily divides a 
population of legislators and governors into groups from which a correlation between 
ideology and policy making can be measured.  The corollary measurement, through use 
of the elected body as proxy of the state’s population, describes the vaccine policy 
adoption over entire state’s population. 
Similarly, the dependent variables of proposal or passage of a mandate and 
proposal or passage of a funding bill represent the adoption of a vaccine policy as an 
innovation.  As previously mentioned, individual adoption is difficult to ascertain within 
the scope of this paper.  As such, the vaccine policies proposed or passed in state 
governments serve as a proxy for individual adoption, just as the elected serve as proxy 
for the states’ individuals.   
 The Trialability, Observability, and complexity aspects of the Diffusion of 
Innovations theory serve act as constants for this study.  The study represents a snapshot 
in time across the United States, and the study’s scope is limited to the innovation of 
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Gardasil alone.  Trialability, Observability, and Complexity are characteristics that are 
more typically used to compare between innovations and the results of an innovation over 
time.  As such, these dynamic characteristics are “frozen” as constants because there is no 
baseline for comparison between states for these characteristics.   
The Diffusion of Innovations concepts discussed assist the evaluation of policy 
diffusion.  Through measuring the association between state characteristics and the 
diffusion of HPV vaccine policy across states a policy diffusion trend may emerge.  The 
results of the logistic regression analyses are reviewed in depth in Chapter IV. 
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CHAPTER IV 
 RESULTS 
Descriptive Statistics 
HPV vaccine mandates have been proposed or enacted in 26 (52.0%) states.  HPV 
vaccine funding initiatives or a general increase in state vaccine funding legislation have 
been proposed or enacted in 9 (18.0%) states.  See Table 1.  Data from 11 (22.0%) states 
were unreported.   
Table 1. Descriptive Statistics: HPV Vaccine Proposed and Enacted Policy 
  Yes Missing
Dependent Variable n (%)  n (%)
           
HPV Vaccine School entry Mandate (Yes) 26 52  0 0
Legislated HPV Vaccine Funding and General Vaccine Funding Increase 
(Yes) 
9 18  11 22
 
In total, 25 states have proposed an HPV vaccine mandate and one state (Texas) 
has implemented a state vaccine mandate for school entry as of March 2007.  See Figure 
2.  As of March 2007, seven states have proposed an increase in vaccine funding, while 
two states have approved an increase in vaccine funding.  However, 11 states are missing 
data.  See Figure 3. 
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Figure 2. Proposed and Enacted HPV Vaccine School Entry Mandates by State 
(Women in Government, 2007a)  
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Figure 3. Proposed and Enacted HPV Vaccine or General Vaccine Program Funding by State 
(National Conference of State Legislatures, 2007)
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State political characteristics are shown below in Table 2.  The 2006 Gubernatorial party 
affiliation was relatively even across the 50 states:  22 Republicans (44%) and 28 
Democratic (28%).   State legislatures were also divided evenly with Republicans holding 
majorities in 20 states (40%) and Democrats holding majorities in 19 states (38%).  In 10 
states (20%), no clear majority was held by a single party.   One state’s data (Nebraska) 
was missing from this variable because Nebraska is a unique state with a unicameral, 
nonpartisan legislature (Adams, 2006). 
Table 2. Descriptive Statistics: State Political Characteristics 
    Missing 
Independent Variable n (%)   n (%) 
            
Gubernatorial Party Affiliation 50 100   0 0 
Republican 22 44       
Democrat 28 56       
Legislature Party Majority 49 98   1 2 
Republican 20 40       
Democrat 19 38       
Mixed 10 20       
 
State health characteristics are shown in Table 3.  The data source for cervical 
cancer incidence rates did not include data on six states (National Cancer Institute, 2006).  
The median cervical cancer incidence rate per 100,000 women was 7.7.  The Pap 
screening percentage had a range of 11.6 and a median of 86.0.  Only Hawaii was 
missing from the primary data source.  The median percent of uninsured women was 
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16%.  No data was missing from the reported rate of uninsured women by state.  The 
United Health Foundation overall state health score median was 3.7.  No data were 
missing from this variable. 
 
Table 3. Descriptive Statistics: State Health Characteristics 
Independent Variable Median Range (Min, Max)  N Missing
Cervical Cancer Incidence  7.70  6.5 (4.4, 10.1)  44 6 
Pap Screening Percentage 86  11.6 (78.2, 89.8)  49 1 
Percentage of Women Uninsured 16  20 (9, 28)  50 0 
United Health Foundation Score 3.7  41.6 (-20.4, 21.2)  50 0 
 
Logistic Regression Analysis  
Since this study was conducted using dichotomous dependent variables, logistic 
regression analysis was chosen to evaluate to association between the independent and 
dependent variables.  The logistic regression model includes the variables of state policy 
proposed or enacted (either HPV vaccine school entry mandate or HPV vaccine or 
general vaccine funding legislation), cervical cancer incidence, Pap screening rate, 
percentage of uninsured women, the United Health Foundation score, political control of 
legislature, and gubernatorial party affiliation.  In addition to the multivariable logistic 
regression model, univariate logistic regression models were analyzed to evaluate the 
significance of each variable to assist in model building independent from the full model.   
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The hypothesis (H1) that there is an association between mandating use of or 
funding for the HPV vaccine and such variables as state health and political 
characteristics (for the time period studied) was neither proven nor disproved.  When 
using logistic regression analysis to test the association between the proposal or 
enactment of an HPV vaccine mandate and independent variables, only one variable 
(cervical cancer incidence rate) showed a significant association with the majority 
acceptance of an HPV vaccine school entry mandate.  Within the multivariate model of 
HPV vaccine school entry mandate, cervical cancer incidence rate showed an odds ratio 
of 3.54 with a strong significance of 0.05 (Table 4).   For each unit increase of cervical 
cancer, the probability of that state proposing or enacting a school entry HPV vaccine 
mandate increases 3.5 times.  When examining the univariate analysis, the association is 
somewhat weaker, but it is extremely significant (0.019).  For each unit increase of 
cervical cancer within the univariate analysis, the probability of that state proposing or 
enacting a school entry HPV vaccine mandate increases 1.82 times.  Other independent 
variables included in the model were not shown to be associated with proposed or 
enacted HPV vaccine mandates.  Similarly, HPV vaccine funding or general vaccine 
program funding shows no associations with the independent variables.  See Table 5. 
To test the validity of the logistic regression results, the same regression analysis 
was conducted using the latest available data on HPV state mandates and funding policy.  
The data was collected in the same manor and from the same sources as the data used in 
this study (March 2007) as noted in Chapter III; however, policy actions had been 
updated to October 2007 (National Conference of State Legislatures, 2007; Women in 
Government, 2007b).  The logistic regression was conducted using the same methods and 
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analyses and the results yielded virtually identical results.  As with the March 2007 data, 
the October 2007 data showed cervical cancer was the only significant variable 
associated with HPV state policy mandates.  No additional associations were shown 
between the independent and dependent variables.  These results are available in the 
Appendices.  
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Table 4. Logistic Regression Model: HPV Vaccine School Entry Mandate Proposed or Enacted     
   Univariate Model   Multivariable Model 
  OR  95% CI  Sig.   OR  95% CI  Sig. 
                     
Cervical Cancer Incidence   1.823  1.103 - 3.011  0.019   3.540  1.462 - 8.572  0.005 
                     
Pap Screening Rate  1.040  0.831 - 1.301  0.733   1.207  0.859 - 1.695  0.277 
                     
Percentage of Women Uninsured  1.010  0.899 - 1.134  0.872   1.015  0.791 - 1.303  0.907 
                     
United Health Foundation Score  0.991  0.944 - 1.040  0.721   1.099  0.981 - 1.231  0.102 
                     
Legislative Majority - Democratic  0.727  0.228 - 2.316  0.590   1.938  0.358 - 10.501  0.443 
                     
Gubernatorial Party Affiliation  1.200  0.392 - 3.676  0.750   1.409  0.321 - 6.193  0.650   
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Table 5. Logistic Regression Model: HPV Vaccine or General Vaccine State Funding Increase    
   Univariate Model   Multivariable Model 
  OR  95% CI   Sig.   OR  95% CI  Sig. 
                   
Cervical Cancer Incidence    0.639  0.344 - 1.188  0.157   0.618  0.259 - 1.479  0.280
              
Pap Screening Rate  1.041  0.760 - 1.426  0.801  1.187  0.700 - 2.012  0.524
              
Percentage of Women Uninsured  1.032  0.886 - 1.202   0.690  1.162  0.813 - 1.661  0.409
              
United Health Foundation Score  1.001  0.937 - 1.069  0.977  1.042  0.886 - 1.226  0.620
              
Legislative Majority - Democratic  0.956  0.213 - 4.284  0.953  1.361  0.115 - 16.128  0.807
              
Gubernatorial Party Affiliation  1.635  0.365 - 7.326  0.521  1.665  0.257 - 10.774  0.593
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CHAPTER V 
DISCUSSION AND CONCLUSION 
Summary of Results 
 
As shown in Chapter IV, the results of the study neither prove nor disprove the 
hypothesis (H1) that there is an association between mandating use of or funding for the 
HPV vaccine and such variables as state health and political characteristics (for the time 
period studied).  Since conclusive results supporting or rejecting the hypothesis have not 
been demonstrated, further studies will be necessary to determine the extent that state 
health and political characteristics may be associated with state policy diffusion.  The 
notable logistic regression results will be summarized below.  
The state health characteristics had a variance of significance in association with 
state proposal or passage of a HPV school entry mandate.  The logistic regression 
analyses showed a significant association between rates of cervical cancer and the 
likelihood that a state had implemented or proposed a HPV vaccine school entry 
mandate.  States with high cervical cancer incidence rates (per 100,000 women) were 
significantly more likely to have proposed or enacted a HPV vaccine school entry 
mandate.  However, the logistic regression analyses showed no association between other 
state health characteristics used in this study and the likelihood that a state implemented 
or proposed a HPV vaccine school entry mandate.  Similarly, no association existed 
between state health characteristics and proposed or enacted state funding allocated for 
HPV vaccine or general vaccine programs. 
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The logistic regression analysis did not show associations between state political 
characteristics and the likelihood of a state proposing or enacting school vaccine 
mandates or vaccine funding policy.  Neither gubernatorial party affiliation nor state 
legislature party majority were associated with HPV vaccine mandate.  Similarly, a 
state’s likelihood of proposing and enacting a funding initiative for HPV vaccine or 
general vaccine programs had no association with either state political characteristics 
examined in this study. 
 
Implications 
Although the hypothesis was neither proved nor disproved, there are some 
implications for the results of this study.  Specifically, there are three implications which 
directly relate to this study: relative advantage, compatibility, and dysfunction.  
 The association between mandate and cervical cancer incidence may speak to the 
concept of relative advantage.  The study found that as the risk factor of cervical cancer 
incidence increased, the likelihood that a mandate would be proposed or passed also 
increased.  The reasons for this are unknown.  Since Gardasil®, as designed, prevents 
cervical cancer, it may be that state policymakers understood Gardasil®’s role as a 
cervical cancer reduction tool or perhaps they were influenced by the result of advocacy 
by Merck or others.   That states with high incidence tend to propose or enact mandate 
policy may also suggest that those states’ policymakers may have wanted to find a 
solution to prevent the long-term costs associated with high cervical cancer incidence.  In 
these states, the risk of not innovating was higher, and when coupled with the costs of 
treatment, the cost-benefit of innovating was reduced.  
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In states with lower cervical cancer incidence, the lower relative advantage of 
innovating may have slowed their policy adoption.  The lower risk states may experience 
a higher relative cost of adopting, as they are likely to spend less on cervical cancer 
treatment per capita than would a high cervical cancer incidence state.  Moreover, the 
higher relative cost to prevent cervical cancer per capita, i.e., the costs associated with the 
vaccine compared to the current treatment per capita costs may explain the slow adoption 
of HPV policy in lower cervical cancer incidence states.  The idea of relative advantage, 
as seen within the context of both high and low incidence states, supports the association 
shown in the study.  The empirical rational for innovation adoption may be weaker in 
lower cervical cancer states. 
The lack of association between state political characteristics and state HPV 
policy may serve to illustrate that ideology did not significantly influence policymakers’ 
HPV policy decisions.  This has important implications when viewed as compatibility.  
Traditional Diffusion of Innovations theory would claim that compatibility has a 
significant impact on adoption rates (as discussed in Chapter II).  However, instead of 
seeing a division of mandate or funding along party lines, the study found that regardless 
of state political characteristics, the only association with policy action was with cervical 
cancer incidence.  While this may illustrate a bipartisan effort to overcome a common 
threat, it is possible that the newness of the innovation has yet to diffuse even among 
social liberals.  Nevertheless, it is notable that Democratic and Republican representative 
affiliation was not associated with HPV policy proposed or enacted. 
Finally, the study found that a dysfunction between state mandate policy and 
funding policy existed in that the two were not associated with the same variable 
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(cervical cancer).  The study showed that mandate proposal or passage was significantly 
associated with cervical cancer incidence rates.  However, the study did not find the same 
correlation with proposed or passed HPV vaccine funding or general vaccine funding.  
Several scenarios could account for the dysfunction between mandate and funding.  One 
possibility is that the reason for this lack of correlation is that policymakers may tend to 
create a mandate prior to funding a vaccine.  The inconsistency demonstrated between the 
two HPV vaccine policies may be due to other factors not reviewed in this study, such as 
variation in state budgets. 
 
Limitations 
Given the observational nature of this study, a few limitations exist.  These 
limitations include: the inability to meaningfully assess the impact of lobbying from 
special interest groups like Merck, use of secondary data instead of primary, the use of 
proxies to establish ideological compatibility with innovation adoption, and the short 
period of time elapsed since Gardasil®’s FDA approval and the ACIP recommendation. 
The significant limitation of this study is the verified involvement of special 
interest lobbies discussed in Chapter II.  Merck’s direct involvement with WIG to lobby 
for vaccine mandates of Gardasil® may have added to the significance shown in the 
study between states with high cervical cancer incidence and state mandates proposed 
and enacted.  Rationally speaking, Merck may have selected those states for the higher 
relative advantage.  High cervical cancer incidence states already would have an 
empirical rationale for adopting, which might reduce the cost to market the policy 
innovation of a mandate for the vaccine.  If their lobby efforts were successful, there 
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exists a possibility that the significance of cervical cancer as a factor affecting the 
likelihood of a proposed or passed mandate could have been overemphasized. 
While Merck’s involvement is documented, other special interest groups may 
have swayed the political process.  Both social conservatives and social liberals may use 
special interest lobbies to advance their position, but the impact of special interest groups 
was not measured in the study.  
A second limitation of this study is the use of secondary data.  A more thorough 
survey of individual policymakers may have yielded more telling results and may have 
provided more information about how HPV policy is diffused through the political 
process.  However, the resources and scope of this study eliminated this possibility. 
The use of proxies to establish ideological compatibility with innovation adoption 
also limits the study.  Proxies, while a convenient substitute for the purpose of this study, 
do not always mimic their assigned host.  One example of a lack of mimic between origin 
and proxy evident in this study may be the nature of political assignment.  Here, while 
politicians typically self-identify a single political party, many of their constituents may 
not self-identify with a single political party.  Moreover, elected official’s political party 
and ideology reflects only the party and ideology of the majority of voters, rather than the 
whole population represented by the official.   
A final limitation is the short period of time elapsed since FDA approval and 
ACIP recommendation of the vaccine.  Given that preventive innovations are slower to 
adopt than other innovations, the study was conducted at the infancy of the policy 
innovation.  Furthermore, no “trial by others” at the state level exists.  Follow-up studies 
may demonstrate differing results as time passes. 
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Recommendations for Policymakers 
A lack of mandate or subsidized funding for vaccines may result in negative 
health outcomes for disadvantaged populations.  As discussed in Chapter II, lower socio-
economic groups do not traditionally have high rates of vaccination in the absence of 
mandates and funding.  If the lower socioeconomic groups do not receive the vaccination, 
the population will be at increased risk of the vaccine-preventable disease.  As it relates 
to HPV, the long term disparity in HPV vaccination coverage rates could result in higher 
rates of cervical cancer among the disadvantaged socioeconomic groups.  Given the 
potential disparities that may arise between socioeconomic groups, remedies should be 
addressed. 
Where high incidence is coupled with a large population of underprivileged 
children who may be at high risk of not having access to the vaccine, mandates should be 
put in place.  By mandating the vaccine, policymakers ensure access to the least 
advantaged by enforcing compliance as a school entry mandate.  The result likely would 
be a reduction in statewide cervical cancer incidence and a reduction in treatment costs 
associated with cervical cancer for the state. 
Where there is a mandate, states should provide funding to adequately cover the 
costs of vaccinating underprivileged children.  Without funding, lower income families 
are at risk of not being able to access the vaccine, which may result in the loss of state 
services, like childhood education (as discussed in Chapter II).  Funding ensures 
disadvantaged children the opportunity to adopt. 
States with low cervical cancer incidence rates should wait to adopt HPV vaccine 
mandates to evaluate to cost-benefit of policy adoption.  By waiting, low cervical cancer 
   
53 
 
incidence states could use “trial by others” to determine if potential unintended 
consequences are bearable.  The knowledge gained by “trial by others” would confirm or 
discredit the relative advantage of the innovation for that particular state.  In cases where 
public outcry for mandate is high, state policymakers in low incidence states should 
consider a funding only option. 
Finally, policymakers should conduct a case study on Texas, since Texas was the 
only state to have enacted HPV vaccine mandate policy at the time of the study.   A case 
study could help states understand the challenges and opportunities associated with 
implementing a state HPV vaccine mandate.   
 
Recommendations for Research Scientists 
Research scientists should utilize population surveys in future studies of 
innovation for more accurate individual adoption patterns.  For example, the CDC 
National Immunization Survey (NIS) annually conducts surveys to determine vaccine 
attitudes and usage across the U.S.  The NIS survey data is planning to add questions 
starting in 2009 about the HPV vaccine (Singleton, Wooten, & Jain, 2007).  The future 
NIS data could measure vaccine adoption rates among the population to evaluate the 
groups of people adopting the innovation. 
 
 
Recommendations for Improving the Adoption of Gardasil® 
The focus of any marketing effort to encourage adoption of the HVP vaccine 
should be on educating key stakeholders about the association between HPV and cervical 
cancer.  This allows the medical innovation to gain majority acceptance and start 
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movements toward greater adoption.  By allowing families additional time to weigh the 
relative advantage of innovation adoption and discuss it with their healthcare provider, 
families may feel free to make the best health decision for their children.  This also 
avoids the possible incompatibility with groups that oppose the vaccine. 
Marketing which targets opinion leaders, such as healthcare providers and faith-
based organizations, in education efforts also is an important strategy for diffusion of the 
HPV vaccine innovation.  It is essential to educate these opinion leaders on the 
importance of adoption of the vaccine so they can give informed advice to others in their 
community.  This may have a positive effect on innovation adoption by increasing the 
moral compatibility of the innovation through the demonstrated acceptance of community 
leaders. 
Change agents should be rallied to engage community organizations that 
encourage voluntary vaccine adoption.  This may reduce the need for a burdensome 
mandate, especially in low incidence states.  For example, school districts should provide 
immunization drives.  Given the plethora of vaccines, parents may appreciate the 
opportunity to ensure compliance with required state mandates, and provide proof of all 
vaccinations in a “one-stop-shop” idea.  Moreover, if the vaccines could be provided at 
reduced cost voluntary adoption may increase.   
Finally, Merck should be encouraged to provide discounted or donated vaccine to 
underprivileged groups, the states, or organizations that serve such groups.   
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Conclusion 
 HPV prevalence as an STI has been documented.  It also has been demonstrated 
that Gardasil®, as an innovation, addressed the looming risk of treatment of cervical 
cancer and genital warts.  The study further demonstrated that Gardasil®, as an 
innovation, generally follows the notion of a preventive innovation as described by the 
Diffusion of Innovations theory.  Moreover, it was determined through logistic regression 
models that cervical cancer incidence affects the likelihood that a state may propose or 
enact a mandate requiring the HPV vaccine for school entry.  Using the Diffusion of 
Innovations lens, the correlation roughly equates to a high relative advantage for high 
incidence states. 
While several avenues for policymakers, research-scientists, and leaders exist, a 
multidisciplinary, multi-tiered approach seems to address the complex nature of policy 
adoption among varying populations in varying states that each have their own unique 
needs and challenges.  Regardless of how an individual state addresses the issue of HPV 
prevalence, their policy should include graduated mandate or funding depending on 
cancer incidence of the state, funding for mandates where mandates exist, and education 
coupled with financial consideration for the underprivileged.  Policymakers may lack the 
understanding that funding alone may be an economical resolution to their state’s cervical 
cancer incidence rate by immunizing a large percentage of the state’s population without 
engaging in the political battles associated with the debates for a mandate.  Additional 
study on reactions of states over the next few years is recommended. 
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